1. GPCR/G Protein
    Neuronal Signaling
  2. Cholecystokinin Receptor
  3. A71623

A71623 

Cat. No.: HY-P1096
Handling Instructions

A71623, a CCK-4-based peptide, is a potent and highly selective CCK-A full agonist. The IC50s for A-71623 are 3.7 nM in guinea pig pancreas (CCK-A) and 4500 nM in cerebral cortex (CCK-B) in radioligand binding assays, respectively.

For research use only. We do not sell to patients.

A71623 Chemical Structure

A71623 Chemical Structure

CAS No. : 130408-77-4

Size Stock
100 mg   Get quote  
250 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Top Publications Citing Use of Products
  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

A71623, a CCK-4-based peptide, is a potent and highly selective CCK-A full agonist. The IC50s for A-71623 are 3.7 nM in guinea pig pancreas (CCK-A) and 4500 nM in cerebral cortex (CCK-B) in radioligand binding assays, respectively[1].

IC50 & Target

IC50: 3.7 nM (CCKA receptor in radioligand binding assays)[1]

In Vitro

In guinea pig gastric glands, the affinities of A-71623 for the cholecystokinin (CCK)-B/gastrin receptor were 11 μM[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

A71623 (A-63387; i.c.v., but not i.p., injections) reduces food intakes and suppresses intakes of a liquid diet in both deprived and sated rats[2].
A71623 dampens Purkinje neuron pathology and associates deficits in motor performance in Pcp2-ATXN1[30Q]D776;Cck-/- and Pcp2-AXTN1[82Q] mice[3].
A71623 improves motor performance of Pcp2-ATXN2[127Q] SCA2 mice[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Adult male, Sprague-Dawley rats[2]
Dosage: 5 μL
Administration: Intracerebroventricular (i.c.v) administration, A-71623 was infused using a 28 gauge injection cannula in a volume of 5uL over 60 s
Result: Reduced food intakes and suppressed intakes of a liquid diet.
Animal Model: ATXN1[30Q]-D776, ATXN1[82Q]-D776, ATXN2[127Q], and WT/FVB/NJ mice [3]
Dosage: 0.02 mg/kg/day
Administration: Osmotic minipumps containing either A71623 (0.02mg/kg/day) were implanted intraperitoneally (i.p.)
Result: Treatment dampened Purkinje neuron pathology in ATXN1[30Q]D776;Cck-/- mice and ATXN1[82Q] mice.
Improved motor performance in ATXN2[127Q] mice.
Molecular Weight

840.96

Formula

C₄₄H₅₆N₈O₉

CAS No.
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Salutation

Applicant Name *

 

Email address *

Phone number *

 

Organization name *

Department *

 

Requested quantity *

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
A71623
Cat. No.:
HY-P1096
Quantity:
MCE Japan Authorized Agent: